OPKO Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPK research report →
Range $2.25 – $4
Price Chart
About the company
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets.
- CEO
- Phillip Frost
- IPO
- 1995
- Employees
- 2,275
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on OPK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.17B
- P/E
- -8.39
- PEG
- 0.08
- P/S
- 2.40
- P/B
- 1.08
- EV/EBITDA
- -48.59
- Div Yield
- 0.00%
- Gross Margin
- 38.64%
- Op Margin
- -25.46%
- Net Margin
- -29.51%
- ROE
- -12.41%
- ROIC
- -5.77%
Latest fiscal year · YoY change
- Revenue
- $606.88M-14.9%
- Gross Profit
- $128.05M-58.8%
- Op Income
- $-218,985,000
- Net Income
- $-225,680,000-324.0%
- EPS
- $-0.30-291.1%
- OCF Growth
- +2.7%
- FCF Growth
- +8.5%
- 52W High
- $1.86
- 52W Low
- $0.98
- 50D MA
- $1.61
- 200D MA
- $1.37
- Beta
- 1.53
- RSI (14)
- 46
- Avg Volume
- 3.81M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
OPKO reported modest top-line growth in continuing operations, improved profitability in Global Products, and a major strategic reset as the planned LabCorp sale will exit diagnostics and leave the company focused on biotech and commercial products.· November 4, 2026
- Continuing operations revenue rose 16% year over year in Q3 to $65.4 million, versus $56.4 million last year.
- Global Products was profitable in the quarter, with operating income of $6 million versus an operating loss of $1.2 million a year ago.
- Innovative Biotech remained loss-making, with an operating loss of $26.8 million as R&D activity increased across early-stage programs.
- OPKO is withdrawing full-year consolidated guidance because of the pending LabCorp transaction; it now guides Q4 continuing revenue of $62 million to $72 million.
- Management highlighted multiple pipeline milestones ahead in 2027, including clinical updates for MDX-2001, MDX-2003, MDX-2004, and OPKO-88006.
OPKO reported third-quarter 2026 consolidated revenue of $65.4 million, up from $56.4 million in Q3 2025. Revenue from continuing operations grew 16% year over year. Global Products revenue was $48.4 million, with product revenue up 11% to $41.8 million and operating income of $6 million versus an operating loss of $1.2 million last year. Innovative Biotech revenue was $17 million, including Pfizer gross profit share of $8.7 million and BARDA funding of $7.5 million, with an operating loss of $26.8 million versus $22.5 million a year ago. Consolidated operating loss improved to $31.4 million from $33.6 million, while R&D expense was $32.2 million and depreciation and amortization was $18.9 million. The company ended the quarter with $403.2 million in cash, cash equivalents and restricted cash. For Q4, OPKO expects continuing-operation revenue of $62 million to $72 million, product revenue of $41 million to $46 million, licensing/collaboration/other revenue of $21 million to $27 million, Pfizer gross profit share of $12.5 million to $15 million, and BARDA funding of $3 million to $5 million. It expects continuing-operation costs and expenses of $100 million to $105 million, including R&D of $32 million to $35 million. For full-year 2026 continuing operations, OPKO updated guidance to revenue of $268 million to $278 million and costs and expenses of $390 million to $395 million, with R&D of $125 million to $130 million and depreciation and amortization of about $75 million. The company also said it expects approximately $40 million of loss from discontinued operations in Q4, or about $0.05 per share. The LabCorp deal is for approximately $722 million in cash at closing, subject to an adjustment, plus up to $150 million of royalty payments tied to 4Kscore revenue over 10 years.
Phillip Frost framed the LabCorp transaction as a defining moment that completes OPKO’s exit from clinical lab services and lets management focus on biotech innovation and the global products business. He emphasized a disciplined capital-allocation model: build assets, validate them, monetize at the right time, and redeploy capital into higher-return opportunities. His tone was upbeat and strategic, with emphasis on refocusing the company and continuing to invest in the pipeline and share repurchases.
Adam Logal focused on the financial reset from the LabCorp sale and the resulting change in reporting, with BioReference now classified as held for sale and treated as discontinued operations. He said OPKO ended Q3 with $403.2 million in cash, had strengthened the balance sheet with $125 million of nondilutive financing from Healthcare Royalty, and repurchased about 7.2 million shares for $10.6 million at an average price of $1.48. He also noted about $84.3 million remains under the buyback authorization and said the board may consider expanding repurchases further as the deal nears closing. On future cash use, he suggested annual investment of around $100 million into operations would not be unreasonable if programs accelerate, while noting cash flow from global pharma and partner products should help support the business.
Analysts focused heavily on what the LabCorp sale means for capital return and on the timing and nature of early data from the ModeX pipeline. Management said more clarity on shareholder returns will come closer to closing, but indicated the board will likely consider accelerating and expanding buybacks; they also said the cash-generating global pharma business and partner royalties should help offset biotech spending. On MDX-2001 and MDX-2004, management said IV dose escalation is ongoing, subcutaneous dosing is planned for 2027, and the team is looking for safety, pharmacology, and early efficacy signals, with basket-trial-style development likely for MDX-2004. They also said NGENLA is performing in line with expectations across geographies, while Mazdutide royalties are effectively being used to service the royalty-backed notes until the cap is reached.
The call reinforced that OPKO is becoming a more focused, better-capitalized company after the LabCorp transaction, with substantial cash expected at closing and additional royalty upside on 4Kscore. Management pointed to improving Global Products profitability, continued growth in NGENLA and Rayaldee, and a pipeline with multiple potential readouts over the next year to two years.
The biggest near-term risk is execution around the LabCorp closing and the transition services period, plus the reported roughly $40 million Q4 loss from discontinued operations. The biotech pipeline is still early, with most assets in dose-escalation or pre-readout stages, and management repeatedly cautioned that subcutaneous dosing and later-stage development depend on safety, tolerability, and emerging data.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 43.1%
- Shares Outstanding
- 742.51M
- Float Shares
- 319.92M
of shares held by institutions
229 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rubric Capital Management LP | 47.79M | 0 |
| Blackrock, Inc. | 36.98M | ▲ 746.67K |
| Vanguard Group Inc | 32.46M | ▼ 5.08M |
| Vanguard Capital Management LLC | 14.97M | ▲ 469.77K |
| Vanguard Portfolio Management LLC | 14.93M | ▲ 165.21K |
| Geode Capital Management, LLC | 11.05M | ▼ 530.76K |
| State Street Corp | 10.65M | ▲ 343.63K |
| Goldman Sachs Group Inc | 7.04M | ▼ 639.53K |
| Whitefort Capital Management, LP | 4.51M | ▲ 258.07K |
| Northern Trust Corp | 3.76M | ▲ 136.82K |
| Sixth Street Partners Management Company, L.P. | 3.60M | ▲ 3.60M |
| Charles Schwab Investment Management Inc | 3.60M | ▲ 22.94K |
Held by 208 ETFs
Biggest fund positions in OPK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | PAGANELLI JOHN A | sell | 4,426 |
| Nov 5, 26 | PAGANELLI JOHN A | sell | 9,175 |
| Jul 24, 26 | Logal Adam | other | 53,266 |
| Jul 24, 26 | Rubin Steven D | other | 53,266 |
| Jun 18, 26 | Lachman Prem A | other | 30,000 |
| Jun 18, 26 | MEDEL ROGER MD | other | 30,000 |
| Jun 18, 26 | PAGANELLI JOHN A | other | 30,000 |
| Jun 18, 26 | PFENNIGER RICHARD C JR | other | 60,000 |
| Jun 18, 26 | UPPALURI SUBBARAO V | other | 80,000 |
| Jun 18, 26 | Yu Alice Lin-Tsing | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OPK coverage
Recent articles, reports, and earnings notes.
No research on OPK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPK report →Here's Why You Should Retain OPK Stock in Your Portfolio for Now
zacks.com · Nov 18
What OPKO Health (OPK) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 4
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
globenewswire.com · Nov 4
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
globenewswire.com · Oct 28
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
globenewswire.com · Oct 27
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
zacks.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.